Bristol-Myers Squibb: A Potential Comeback In Healthcare
Bristol-Myers Squibb(BMY) Seeking Alpha·2024-08-06 18:32John Scott/DigitalVision via Getty ImagesDespite lingering skepticism about Bristol-Myers Squibb's future (NYSE:BMY) on Wall Street in recent months, fueled by investor concerns about Eliquis facing patent expirations in 2026, the company pleasantly surprised me with its second-quarter financial results, thanks in part to strong sales in its cardiovascular franchise that offset a muted 11% year-over-year sales growth in its blockbuster PD-1 inhibitor Opdivo due to increasing competition from Merck's Key ...